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Background: The underlying mechanisms of incomplete immune reconstitution in treated HIV-positive
patients are very complex and may be multifactorial, but perturbation of chemokine secretion could play a
key role in CD4+ T-cell turnover.
Methods: We evaluated the circulating baseline and 48-week follow-up concentrations of SDF-1/CXCL12, fractal-
kine/CX3CL1, MCP-1/CCL2, MIP-a/CCL3, MIP-b/CCL4 and RANTES/CCL5, and we estimated their association with
CXCL12, CX3CR1, CCR2, CCL5 and CCR5 single nucleotide polymorphisms (SNPs) to investigate multiple chemo-
kine-chemokine receptor signatures associated with immune dysregulation preceding poor immune recovery.
Findings: The circulating concentrations and gene expression patterns of SDF-1/CXCL12 (CXCL12 rs1801157)
and MCP-1/CCL2 (CCR2 rs1799864_814) were associated with immune recovery status. CCR2
rs1799864_814 and CCR5 rs333_814 (D32) determine the baseline plasma RANTES and MIP-a concentra-
tions, respectively, in participants with poor immune response.
Interpretation: SDF-1/CXCL12 and MCP-1/CCL2 could be considered prognostic markers of immune failure
despite suppressive antiretroviral therapy. The strong linkage disequilibrium (LD) between CCR2
rs1799864_814 and CCR5 rs1800024 indicated that the alleles of each gene are inherited together more often
than would be expected by chance.
Funding: This work was supported by Fondo de Investigacion Sanitaria and SPANISH AIDS Research Network
(ISCIII-FEDER); AGAUR and Gilead Fellowship. FV and YMP are supported by grants from the Programa de
Intensificacion (ISCIII) and Servicio Andaluz de Salud, respectively. JVG,EY and LR are supported by the Insti-
tuto de Salud Carlos III (ISCIII). AR is supported by Departament de Salut, Generalitat de Catalunya and by the
Instituto de Salud Carlos III (ISCIII).






Polymorphisms variantsartment of Internal Medicine
na Joan XXIII, IISPV, Universi-
43007
idal).
# These authors contributed equally to this paper, and should be considered as pri-
mary co-authors.
* These authors contributed equally to this paper, and should both be considered as
senior co-authors.
V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2 E. Yeregui et al. / EBioMedicine 62 (2020) 103077Research in context
residues. Chemokines signal through cell surface G protein-coupledEvidence before this study
Chemokines are chemotactic cytokines that signal through cell
surface G protein-coupled heptahelical chemokine receptors to
control the migration and positioning of immune cells to the
sites of infection and injury. They are critical for the function of
the innate immune system. Accordingly, the chemokine-che-
mokine receptor system clearly plays an important role in the
HIV life cycle, disease progression, and HIV reservoir establish-
ment. Thus, imbalances of cytokine-chemokine levels were
hypothesized to be responsible for a lack of appropriate CD4+ T-
cell reconstitution after suppressive cART.
Added value of this study
The present study jointly evaluates a specific remarkable net-
work of chemokines as prognostic and follow-up markers of
immune recovery status by determining circulating concentra-
tions and performing a genetic polymorphism study. This is the
largest, longitudinal study assessing both chemokine genetics
and circulating levels in immune restoration.
Implications of all the available evidence
The chemokine-chemokine receptor system is more complex
than indicated by the study of a selected chemokine and its nat-
ural ligands due to the enormous network existing among the
different chemokines and their receptors. However, we con-
clude that SDF-1/CXCL12, MCP-1/CCL-2 and CCR5 receptors are
key effectors of susceptibility to HIV progression, especially in
terms of immune reconstitution. Our data open a window for
new proof-of-concept studies to explore the individual but also
dual blockage of SDF-1 and MCP-1, as well as CCR2 and CCR5,
as potential therapeutic options for advanced clinical trials
with promising fortunate outcomes.1. INTRODUCTION
Combination antiretroviral treatment (cART) in HIV-positive par-
ticipants aims to suppress HIV replication below detectable levels
and restore the CD4+ T-cell counts. [1] However, approximately 30%
of people living with HIV (PLW) with optimal treatment and fully
suppressed viral replication fail to recover their CD4+ T-cell counts.
[2,3] These patients are referred to as “immunodiscordants” or
“immunological nonresponders” (INRs), and are linked to an
increased risk of disease progression and death compared with PLW
who achieve complete immune reconstitution. [4,5]
The CD4+ T-cell count is the result of the production, destruction,
and trafficking between secondary lymphoid organs and peripheral
tissues of CD4+ T-cells, [2,6] and INRs may have both excessive
destruction and alterations in the production of CD4+ T-cells, result-
ing in an increase in cycling and proliferation before cART. [7]
Although the underlying mechanisms of incomplete immune recon-
stitution are very complex and may be multifactorial, perturbation of
chemokine secretion could play a key role in CD4+ T-cell turnover,
[810] and chemokine modulation has been proposed as a promising
therapeutic strategy to improve immune reconstitution. [11,12]
Chemokines are chemotactic cytokines that control the migration
and positioning of immune cells, most notably leukocytes, to the sites
of infection and injury. [13] They are a large family of small
(812 kDa) proteins that are characterized by the presence of three
to four conserved cysteine residues and that can be classified into
four families based on the positioning of the N-terminal cysteineheptahelical chemokine receptors to perform a variety of functions
aside from chemotaxis, including T cell differentiation and function,
as well as angiogenesis. Thus, investigations regarding multiple cyto-
kine-chemokine signatures associated with immune dysregulation
preceding poor immune recovery are needed to understand the
molecular mechanism involved in this condition and therefore to
develop a useful tool for early detection.
In fact, the connection between the expression of different pro-
inflammatory cytokines and the discordant response encouraged us
to recently explore the role of the IL-7/IL-7R axis in INRs. [10] Since
our results confirmed that improved knowledge of this cytokine and
its receptor in HIV participants could produce new insights regarding
the immune response to ART, we hypothesized that the study of
some selected chemokines related to IL-7/IL-7R axis could help to
identify the molecular mechanisms associated with immune dysre-
gulation preceding a discordant response to ART. Thus, in this study,
we evaluated circulating baseline (pre-ART) and 48-week follow-up
concentrations of stromal cell-derived factor 1 (SDF-1), also known
as C-X-C motif chemokine 12 (CXCL12) (SDF-1/CXCL12), fractalkine/
CX3CL1, monocyte chemoattractant protein-1 (MCP-1/CCL2), macro-
phage inflammatory protein-1 alpha (MIP-a/CCL3), macrophage
inflammatory protein-1 beta (MIP-b/CCL4) and RANTES (regulated
upon activation, normal T cell expressed and secreted), also known
as CCL5, and we also determined whether some selected CXCL12,
CX3CR1, CCR2, CCL5 and CCR5 single nucleotide polymorphisms
(SNPs) are associated with CD4+ T-cell recovery in a previously char-
acterized cohort of HIV participants. [10]
2. MATERIALS ANDMETHODS
2.1. Study design and participants
A multicentre, longitudinal case-controlled study of 502 adult
HIV-positive participants who were consecutively recruited between
2011 and 2013 at the HIV outpatient clinics of the participating hos-
pitals who started their first ART and achieved virological suppres-
sion after ART was performed. [10] Patients were selected from
among those who were receiving a combination of two nucleoside
reverse transcriptase inhibitors (NRTI) plus a nonnucleoside reverse
transcriptase inhibitor (NNRTIs) or a protease inhibitor(s) (PI). A flow-
chart of patient selection and enrolment is provided in Fig. 1 with the
previously defined inclusion/exclusion criteria. [10] Of the selected
patients, 262 were defined as controls (baseline CD4+ T-cell counts
>200 cells/mL), and 240 were cases (baseline CD4+ T-cell counts 
200 cells/mL). Among the cases, 226 could be classified for the
immune recovery study: 118 participants had more than 250 CD4+ T-
cells/mL after 48 weeks of ART (“immunological responders”, IRs),
and 108 participants did not reach the 250 cells/mL CD4+ T-cell
threshold (“immunological nonresponders”, INRs). The threshold of
250 CD4+T-cells/mL to classify patients regarding immune recovery
status was previously validated by the fact that patients receiving
cART with CD4+ T-cells persistently below 250 cells/mL area associ-
ated with worse clinical outcomes [5] and thus, to be consistent with
our previous related work, [10] in this study we maintain the same
threshold criteria.
2.2. Ethics
The study and all research protocols were carried out in accor-
dance with the recommendations of the Ethical and Scientific Com-
mittees from each participating institution and were approved by the
Committee for Ethical Clinical Research by following the rules of
Good Clinical Practice from the Institut d’Investigacio Sanitaria Pere
Virgili (CEIm IISPV)(CEIC 61p/2013). The CEIm IISPV is an indepen-
dent committee, made up of health and nonhealth professionals,
Fig. 1. Flowchart illustrating subject cohort enrolment and analysis. HIV-infected subjects were included and categorized as controls and cases according to the pre-cART CD4+ T-
cell counts. For the immune recovery sub-study group, cases starting cART with T-cell counts below 200 cells/mL were categorized according to their immune status after 48 weeks
of follow-up.
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governing clinical trials and research projects that are carried out in
our region, specifically in terms of methodology, ethics and laws. All
participants gave written informed consent in accordance with the
Declaration of Helsinki.
2.3. General laboratory measurements
Plasma was obtained by centrifugation and was stored at 80 °C
in the IISPV-Biobank until use. HIV-1 infection was diagnosed by a
positive ELISA result and confirmed by Western blot analysis. The
plasma HIV-1 viral load was determined by the Cobas Amplicor HIV-
1 Monitoring Test v 1.5 (Roche Diagnostics, Barcelona, Spain). The
limit of detectability was <20 copies/mL. CD4+ T-cell counts were
analysed using a FACScan flow cytometer (Becton Dickinson, San
Jose, CA, USA).
2.4. Genetic studies
We chose 13 single nucleotide polymorphisms (SNPs) in selected
chemokine and chemokine receptors, with an allelic frequency greater
than 20% in the Iberian Population in Spain (IBS) or the European Popu-
lation (EU) in the NCBI SNP database. In summary, the following 13
SNPs in chemokines were analysed in this study: CXCL12 rs1801157;
CCL5rs2280789, CCL5rs2280788 and CCL5rs2107538; in chemokine
receptors: CX3CR1rs373278_814, CX3CR1rs3732379, CCR2rs1799864,CCR5rs2734648, CCR5rs1799987, CCR5rs1799988, CCR5rs1800023,
CCR5rs1800024 and CCR5rs333_814 were analysed. Genomic DNA was
extracted from peripheral blood with a Qiagen kit (Qiagen, Hilden, Ger-
many) and then the extracted DNA samples (5 ng/mL) were sent to LGC
Genomics Ltd. (formerly Kbioscience Ltd., Herts, UK) for genotyping.
[10] The CCL3/4 copy number variation (CVN) was not considered in
the present study due to the high level of discordance between differ-
ent assays/techniques to measure it and also because CCL3L1CCL4L1
CVN results will be bias by the study design asmentioned below in lim-
itations of the study.
2.5. Plasma chemokine concentrations
Plasma concentrations of human SDF-1 (CXCL12), fractalkine
(CX3CL1), MCP-1 (CCL2), MIP-a (CCL3), MIP-b (CCL4) and RANTES
(CCL5) were measured by a double-antibody sandwich one-step pro-
cess enzyme-linked immunosorbent assay (ELISA) with DuoSet
DY350 (R&D Systems Inc), DuoSet DY365 (R&D Systems Inc),
BMS281INST (eBioscience, The Affymetrix company), DuoSet DY270
(R&D Systems Inc) and DuoSet DY271 (R&D Systems Inc), respec-
tively, according to the manufacturer’s instructions.
2.6. Statistical analyses
Prior to the statistical analyses, the normal distribution and
homogeneity of the variances were tested using a Kolmogorov-
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§ standard deviation (SD), whereas variables with a skewed distribu-
tion were represented as the median (25th percentile  75th percen-
tile) or transformed into a decimal logarithm. Categorical variables
were reported as numbers (percentages). Qualitative variables were
analysed using the x2 test or Fisher’s exact test when necessary.
Comparisons between groups were performed with nonparametric
Kruskal-Wallis (KW) and/or Mann-Whitney (MW) tests for unpaired
samples and a Wilcoxon t-test for paired samples (W). When applica-
ble, Bonferroni post-hoc approach was used in multiple comparison
analyses. Associations between quantitative variables were evaluated
using the Spearman correlation. Allele and genotype frequencies and
the Hardy-Weinberg equilibrium (HWE) were evaluated using
SNPstats software [14]. To estimate the association between chemo-
kine and chemokine receptor genetic polymorphisms and immune
recovery status, we used multiple inheritance models (codominant,
dominant, recessive, overdominant and additive). For each SNP, the
odds ratios (ORs) and 95% confidence intervals (CIs) were calculated
using unconditional logistic regression analysis with adjustment of
the baseline pre-ART CD4+ T-cell counts. In addition, the HaploReg
v4.1 software (https://pubs.broadinstitute.org/mammals/haploreg/
haploreg.php), a bioinformatic tool designed for exploring the anno-
tations of the noncoding variants in haplotype blocks, was used to
evaluate the mechanistic hypothesis of the queried SNP. Statistical
analyses were performed using SPSS (version 21.0, SPSS Inc., Chicago,
IL), and graphical representations were generated with GraphPad
Prism software (version 5.0, GraphPad Inc., San Diego, CA). The
results were considered significant at P < 0.05.
2.7. Role of funders
Funders had no role in the study design and participants’ recruit-
ment, no role in general laboratory measurements, data analysis, and
interpretation of data; no role in the writing of the manuscript, and
no role in the decision to submit the final manuscript for publication.
3. RESULTS
3.1. Patient characteristics
The pre-cART clinical characteristics of the study cohort of HIV-
positive participants (n = 502) were categorized according to the
baseline CD4+ T-cell counts (Fig. 1) and are presented in Table 1. The
patients associated with cases (baseline CD4+ T-cell  200 cells/mL)
were older, presented significantly decreased CD4+ T-cell counts and
increased plasma viral loads compared to controls (baseline CD4+ T-
cell > 200 cells/mL), and they were categorized according to immune
recovery criteria based on CD4+ T-cell counts after 48 weeks of sup-
pressive cART (48w ART) as immunological recoverers (IRs, n = 118)
or immunological nonrecoverers (INRs, n = 108). The INRs were older,
presented significantly lower CD4+ T-cell counts at baseline and were
associated with intravenous drug use at enrolment.
3.2. SDF-1 and MCP-1 are prognostic markers of the immune response
to cART
Higher SDF-1 (P = 0..074), RANTES (P = 0..006) and MCP-1
(P = 0..002) plasma concentrations (non-parametric Mann-Whitney
was used to compare differences between groups, P values h0.05 con-
sidered statistically significant, and P values i 0.05 but < 0.10 were
considered relevant for results interpretation) negatively correlated
with these chemokines to baseline CD4+ T-cell counts (Fig. 2). Of
interest, the baseline SDF-1 and MCP-1 plasma concentrations were
higher in INRs than in IRs. Therefore, these two molecules are related
not only to the pre-cART low CD4+ T-cell count but also to immune
recovery prognosis. In contrast, MIP-alpha (MIP-a) showed a positiveassociation with baseline CD4+ T-cell counts (P = 0.004, Spearman
correlation test). In fact, plasma concentrations of MIP-awere signifi-
cantly higher in controls compared to cases (Table 1, P = 0.006, non-
parametric Mann-Whitney test), although no differences were
observed between INRs and IRs.
The independent association between baseline CD4+ T-cell counts
and plasma chemokine concentrations was corroborated using step-
wise multiple regression analysis with the baseline CD4+ T-cell count
as the dependent variable. The model was statistically significant (F
(3, 198) = 8.316, P < 0.001) and accounted for approximately 10% of
the variance in the baseline CD4+ T-cell counts (R2 = 0.112, adjusted
R2 = 0.098). These observations suggest that lower CD4+ T-cell counts
are primarily predicted by higher plasma MCP-1 and SDF-1 concen-
trations and to a lesser extent by higher plasma viral loads, which
accounted for approximately 5%, 4% and 2% of the variance in the
baseline CD4+ T-cell counts, respectively (Fig. 2b.1). Thus, the poten-
tial for the circulating MCP-1 and SDF-1 baseline values to be prog-
nostic markers of immune status due to poor CD4+ T-cell count
recovery after 48 w cART was analysed using standard regression
analysis with 48w cART CD4+ T-cell count as the dependent variable.
In that case, the model was statistically significant (F(2, 333) = 7,
P = 0.001, standard regression analysis) and accounted for approxi-
mately 4% of the variance in the 48w cART CD4+ T-cell counts (MCP-1
accounted for approximately 3% of the variance). Thus, we confirmed
that these two molecules are related to low CD4+T-cell counts pre-
cART and at 48w, playing an important role in immune recovery
prognosis (Fig. 2b.2). It is important to highlight that the R-squared is
a measure of exploratory power, not fit, and for that reason reporting
the value of R-squared significantly different from 0, even less than
0.7 (generally considered a model with very good fit), indicated that
the regression model had statistically significant exploratory power.3.3. SDF-1 is a marker of poor progression, and the MCP-1& MIP-a are
markers ofDCD4+ T-cells
The circulating plasma SDF-1 and RANTES concentrations remained
significantly elevated in cases compared to controls after cART for 48
weeks (Fig. 3). In fact, the level of SDF-1 was significantly different
between INRs and IRs at both baseline (P = 0.036, non-parametric
Mann-Whitney test) and after 48 w of cART (P = 0.036, non-paramet-
ric Mann-Whitney test), which indicates SDF-1 as not only a prognos-
tic marker of the immune response but also disease progression. On
the other hand, circulating plasma MIP-a levels were higher in con-
trols than in cases after 48w of cART, although no differences were
observed between INRs and IRs. Regarding plasma MCP-1 concentra-
tions, the initiation of ART decreased the circulating chemokine con-
centration in all participants. In fact, the percentage decrease in MCP-1
(DMCP-1) during cART was significant between cases and controls
(P = 0.001, non-parametric Mann-Whitney test) but not between INRs
and IRs (P = 0.100, non-parametric Mann-Whitney test).
Finally, the percentage increase in the CD4+ T-cell counts (DCD4+
T-cell) was calculated to evaluate its association with the percentage
increase/decrease in each chemokine during the 48w of cART. The
DCD4+ T-cell count was positively related to the DMIP-a concentra-
tions (r= 0.137, P = 0.040, Spearman correlation test), and inversely
correlated with the DMCP-1 plasma values (r= 0.124, P = 0.023,
Spearman correlation test). These results corroborated MCP-1 and
MIP-a as general markers of CD4+ T-cell responses to cART follow-up.3.4. Genetic association study of chemokine (CXCL12 and CCL5) gene
variants
Table 2 summarizes the distribution of CXCL12 rs1801157, located
on chromosome 10, and CCL5 rs2280789, CCL5 rs2280788 and CCL5
rs2107538, located on chromosome 17, among the groups, which
Table 1
Study cohort (n = 502) characteristics of the according classification criteria .
Control (n = 262) Cases (n = 240) P-value* IR (n = 108) INR (n = 118) P-value**
Pre-ART clinical characteristics
Age at cART initiation (years) 37 [3145] 39 [3448] 0.001 37 [3342] 42 [3650] <0.001
Male 209 (80.38) 192 (80.67) 0.545 94 (79.67) 83 (76.85) 0.610
Risk factor 0.268 0.004
Heterosexual 89 (34.23) 92 (38.65) 43 (37.07) 47 (43.52)
Homo/Bisexual 128 (49.23) 94 (39.50) 58 (50.00) 35 (32.41)
Intravenous drug abuse 37 (14.23) 47 (19.75) 13 (11.21) 23 (21.3)
Other/Unknown 6 (2.29) 5 (2.10) 2 (1.72) 3 (2.78)
CD4+ T-cell count (cells/mL) 327 [265439] 92 [37162] <0.001 135 [59182] 59 [19116] <0.001
Plasma HIV RNA load (log copies/mL) 4.88 [4.305.26] 5.15 [4.725.61] <0.001 5.08 [4.745.61] 5.27 [4.775.67] 0.587
HCV co-infection (Positive) 38 (16.17) 48 (22.53) 0.257 22 (19.47) 22 (22.68) 0.116
Pre-ART plasma chemokine concentrations
SDF-1 (pg/mL) (n = 377) 0.25 [0.210.30] 0.26 [0.220.30] 0.074 0.25 [0.210.30] 0.26 [0.240.31] 0.036
Log RANTES (pg/mL) (n = 380) 1.45 [0.771.91] 1.75 [1.041.97] 0.006 1.61 [0.971.95] 1.86 [1.111.98] 0.104
Log FK (pg/mL) (n = 345) 0.66 [0.570.79] 0.67 [0.550.76] 0.583 0.66 [0.550.76] 0.68 [0.550.78] 0.304
Log MCP-1 (pg/mL) (n = 345) 2.40 [2.182.61] 2.51 [2.312.73] 0.002 2.47 [2.242.69] 2.58 [2.392.78] 0.037
Log MIP-a (pg/mL) (n = 231) 1.46 [1.241.70] 1.34 [1.211.50] 0.006 1.31 [1.181.49] 1.39 [1.211.55] 0.424
Log MIP-b (pg/mL) (n = 223) 1.69 [1.521.81] 1.64 [1.491.80] 0.471 1.63 [1.491.78] 1.66 [1.451.81] 0.571
Data are presented as n (%) or median (interquartile range). Categorical data were compared by means of a x2 test, whereas continuous data were compared
using non-parametric Mann-Whitney test (P* value for comparison between control and cases, P** value for comparison between IR and INR). P value h 0.05
was considered significant and is highlighted in bold. All P values i 0.05 but < 0.10 were considered relevant for results interpretation and are italicized. INR,
incomplete immune recoverers; IR, immune recoverers.
MCP-1/CCL2, monocyte chemoattractant protein-1; MIP-a/CCL3, macrophage inflammatory protein-1 alpha; MIP-b/CCL4, macrophage inflammatory protein-1
beta; RANTES/CCL5, regulated upon activation, normal T cell expressed and secreted and SDF-1/CXCL12, stromal cell-derived factor 1.
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consistent with the Hardy-Weinberg equilibrium (HWE).
Regarding CXCL12 rs1801157, our results suggested a potential
association between SDF-1 expression and the immune response to
cART (P = 0.065, Fig. 4a). Five inheritance models were fitted, which
correspond to different groupings of the genotypes, and the Akaike’s
Information Criterion (AIC) and Bayesian Information Criterion (BIC)
calculated to select the best model for each specific SNP. In fact, con-
sidering the AIC and BIC scores adjusted for the baseline pre-cART
CD4+ T-cell counts, an association with immune recovery status was
detected with the recessive model (Table 3).
No association was found between the selected CCL5 gene var-
iants and a pre-cART low CD4+ T-cell count or immune response to
cART. However, a pairwise linkage disequilibrium (LD) estimate was
obtained for the CCL5 gene polymorphisms (Table 3b), revealing that
all the SNP marker combinations exhibited perfect LD scores in each
of the analysed groups. Any of the possible haplotypes were related
to low pre-cART CD4+ T-cell counts or to cART-associated immune
recovery (data not sown).3.5. Genetic association study of selected chemokine receptor gene
variants
Table 4 summarizes the characteristics of the CX3CR1
rs3732178_814 and rs3732379, CCR2 rs1799864_814, and CCR5
rs2734648, rs1799987, rs1799988, rs1800023, rs1800024 and
rs333_814 polymorphisms located on chromosome 3 among the
groups, which were in accordance with the data listed in the NCBI
SNP database and the HWE. The genotype frequencies for all selected
chemokine receptor gene variants explored in this study were consis-
tent with the HWE. No association was found between the CX3CR1
gene variants, and pre-cART low CD4+ T-cell counts or immune recov-
ery status. However, our results suggested a potential association
between CCR2 rs1799864_814 and the immune response to cART
(P = 0.076, Table 4 and Fig. 4). Considering the AIC and BIC scores
(adjusted for the baseline pre-cART CD4+ T-cell counts), the associa-
tion was detected for the codominant model (G/A, OR = 0.48, 95%
CI = 0.221.06, P = 0.047). However, the confidence interval includes
1, and thus there is insufficient evidence to conclude that the groups
are statistically significantly different.Regarding CCR5 gene variants, only CCR5 rs1800024 and CCR5
rs333_814 (D32) were related to immune recovery status (Table 4 and
Fig. 4). In the case of CCR5 rs1800024, considering the AIC and BIC
scores (adjusted for baseline pre-ART CD4+ T-cell counts), an associa-
tion was detected with the codominant model (C/T, OR = 0.48, 95%
CI = 0.221.03, P = 0.024 from logistic regression analyses using
SNPstats software). We also found a significant relationship between
poor immune recovery status and the D32 homozygous genotype
(1 allele, Table 5), although the risk was not found to be statistically
significant in the SNP analysis (OR = 2.05, 95% CI = 0.795.34, P = 0.13).
Finally, multipleSNP analysis was performed for all chemokine
receptor variants located on chromosome 3 ordering them by the
correlative chromosome position. LD was found between several
genetic variants (Fig. 4b). Interestingly, among cases, a strong LD was
found between the two chemokine receptor variants, CCR2
rs1799864_814 and CCR5 rs1800024, which were associated with the
immune response in the single SNP analysis, (D’ = 0.9992, P < 0.001,
LD analysis using SNPstats software), indicating that these alleles of
each gene are inherited together more often than would be expected
by chance (Fig. 4b). The haplotypes GCGTGTGCA (OR = 0.12, 95%
CI = 0.020.94, P = 0.044, haplotype analyses using SNPstats soft-
ware) and ATGGACACA (OR = 0.11, 95% CI = 0.020.61, P = 0.013, hap-
lotype analyses using SNPstats software) were associated with the
immune response according to the CD4+ T-cell counts after 48 weeks
of cART (Table 5).3.6. CXCL12 rs1801157 and CCL5 rs2280788 impact the baseline
chemokine values
Then, the impact of the selected chemokine gene variants on cir-
culating chemokine concentrations was explored in cases (INR and
IR) to establish any possible association with immune recovery status
in response to cART (Fig. 5). Interestingly, among the CCL5 gene var-
iants explored in this study, only CCL5 rs2280788 was associated
with circulating chemokine concentrations. Rather than being associ-
ated with plasma CCL5 values, CCL5 rs2280788 was strongly related
to plasma fractalkine (P = 0.008, one-way ANOVA test) and MIP-a
(P < 0.001, one-way ANOVA test) values in IRs and circulating MIP-b
(P = 0.041, one-way ANOVA test) in INRs. Regarding CXCL12
rs1801157, an association was found between this SDF-1 gene
Fig. 2. a) Correlation analysis between the baseline (pre-cART) CD4+ T-cell counts and selected chemokines (Spearman correlation test). Insert shows the baseline circulating con-
centrations of the selected chemokines in INRs (n = 85) and IRs (n = 89) compared with those in a group of control participants (n = 206) (non-parametric Mann-Whitney test).
b) Association of plasma chemokine concentrations to pre-cART low CD4+ T-cell counts (b.1) and immune recovery status (b.2) (Multiple regression analysis). b.1) Stepwise regres-
sion results for the prediction of the baseline pre-cART CD4+ T-cell counts. The dependent variable was baseline pre-cART CD4+ T-cell counts and the independent variables tested
initially were log CV, SDF-1/CXCL12, log fractalkine/ CX3CL1, log MCP-1/CCL2, log MIP-a/CCL3, log MIP-b/CCL4 and log RANTES/CCL5. b.2) Standard regression results for the predic-
tion of immune recovery status. The dependent variable was CD4+ T-cell counts after 48 weeks of cART and the independent variables were SDF-1/CXCL12 and log MCP-1/CCL2.
sr2 = squared semi-partial correlation used to calculated the percentage of the variance.
6 E. Yeregui et al. / EBioMedicine 62 (2020) 103077variant and the circulating SDF-1 concentration in IRs (P = 0.05, one-
way ANOVA test).
3.7. CCR2 rs1799864 and CCR5-D32 determine the chemokine
concentration in INR
No association was found between the selected CX3CR1 variant and
the vast majority of CCR5 gene variants and circulating chemokinevalues. Only CCR5-D32 was significantly related to the plasma MIP-b
concentration in INRs (P = 0.002, one-way ANOVA test), although the
expression of this chemokine in the circulation was not related to pre-
cART CD4+ T-cell counts or to immune response in this study. On the
other hand, the expression of CCR2 rs1799864_814 was significantly
related to the plasma RANTES concentration in INRs, corroborating the
binding of this chemokine to the CCR2 receptor (Fig. 5) and the poten-
tial role in the immune response.
Fig. 3. Longitudinal evaluation of SDF-1/CXCL12 (n = 208 controls, n = 85 INR and n = 88 IR), RANTES/CCL5 (n = 208 controls, n = 85 INR and n = 89 IR), MCP-1/CCL2 (n = 185 controls,
n = 77 INR and n = 80 IR) and MIP-a/CCL-3 (n = 130 controls, n = 48 INR and n = 53 IR) during 48 weeks of cART in INRs and IRs compared to a control group of subjects.
Data are represented as the mean§SEM. Non-parametric Mann-Whitney test, * significant differences to control group and f significant differences to IRs) .
Table 2
General characteristics for the genetic study of CXCL12 (SDF-1) and CCL5 (RANTES) gene variants.
Polymorphism Chr Position Genotype Cases Control P-value Cases P-value HWE
INR IR Control INR IR
CXCL12 rs1801157 C>T chr10:44,372,809 CC 144 (68%) 151 (67%) 0.439 64 (67%) 73 (71%) 0.065 0.054 0.33 0.12
CT 62 (29%) 61 (27%) 27 (28%) 30 (29%)
TT 7 (3%) 13 (6%) 5 (5%) 
CCL5 rs2280789 T>C chr17:35,879,999 TT 156 (75%) 176 (80%) 0.177 75 (77%) 73 (74%) 0.812 0.48 0.63 0.43
TC 47 (23%) 45 (20%) 20 (21%) 23 (23%)
CC 5 (2%) 1 (0%) 2 (2%) 3 (3%)
CCL5 rs2280788 C>G chr17:35,880,401 CC 205 (95%) 219 (95%) 0.948 98 (95%) 96 (96%) 0.767 1 1 1
GC 10 (5%) 11 (5%) 5 (5%) 4 (4%)
CCL5 rs2107538 C>T chr17:35,880,776 CC 135 (64%) 144 (64%) 0.548 64 (66%) 64 (62%) 0.348 0.41 0.16 1
CT 66 (31% 73 (33%) 30 (31%) 31 (30%)
TT 11 (5%) 7 (3%) 3 (3%) 8 (8%)
P-values were calculated by the Chi-square test. HWE, Hardy-Weinberg equilibrium.
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The cytokine-chemokine network is enormously complex with a
large number of different involved molecules (ligands, receptors
and regulatory proteins, among others) that play fundamental roles
in the development and homeostasis of the immune system. [13]
Accordingly, the chemokine-chemokine receptor system clearly
plays an important role in the HIV life cycle, disease progression,
and HIV reservoir establishment, [1517] presenting new perspec-
tive for the development of effective therapeutic approaches in
response to HIV/AIDS susceptibility during the last 10 years. [18] In
this context, the present study aims to investigate the network
associated with the selected CCL chemokines (Fig. 6) which are
linked to our previous work focused on immune reconstitution.
[9,10] Network modeling elucidated the relationship between gluta-
mate metabolism to CCL2/CCR2, CCL5 and CX3CR1 axis in CD4+ T-
recovery [9] and we anticipated that the study of IL-7 and its recep-
tor could support new insights regarding T-cell reservoir in HIV-
positive participants. [10] Based on these findings we firmly
believed that the study of the previously identified chemokinesrelated to IL-7/IL-7R axis may reveal promising results on immune
reconstitution. For that reason, cytokine IL-7 and chemokines CCL2
and CCL5 have been selected as input in the STRING interface to
expand the chemokine-chemokine receptor network and to estab-
lish which chemokine and chemokine receptor candidates will be
included in the present work (Fig. 6). To our knowledge, this is the
first work that jointly evaluates this network of chemokines as
prognostic and follow-up markers of immune recovery status by
determining circulating concentrations and performing a genetic
polymorphism study. Concretely, our main findings were that the
baseline plasma MCP-1/CCL2 and SDF-1/CXCL12 concentrations
accounted for approximately 9% and 4% of the variance of the base-
line and 48w cART CD4+ T-cell counts, respectively, and that, the
CXCL12 rs1801157 was associated with the immune response. Addi-
tionally, regarding chemokine receptors, we demonstrated that
while CCR2 rs1799864_814 and CCR5 rs1800024 revealed a strong
LD, the combination of the different CX3CR1, CCR2 and CCR5 SNPs
analyzed in chromosome 3 resulted in two haplotypes that were
significantly associated with the immune response according to the
CD4+ T-cell counts after 48 weeks of cART.
Fig. 4. Genetic association study of selected chemokine and chemokine receptor gene variants. a) Distribution of CXCL12 rs1801157, CCR2 rs1799864_814, CCR5 rs1800024 and
CCR5 rs333_814 (D32) among cases (n = 100 INR and n = 100 in IR) (P-values were calculated by the Chi-square test). b) Linkage disequilibrium analysis in cases (INRs versus IRs)
for chemokine receptor located on chromosome 3 (n = 450) (Multiple SNP-analysis by SNPstats software).
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were higher in cases compared to those in controls at both baseline
and after 48w cART, but only SDF-1/CXCL12 was crucial for the differ-
entiation among INRs and IRs. Our results suggest that elevated
plasma SDF-1/CXCL12 is a prognostic indicator of low CD4+ T-cell
counts preceding immune failure in response to cART and a follow-
up marker of poor immune reconstitution despite successful viro-
logical suppression during cART. Although increased plasma levels
of SDF-1/CXCL12 were previously related to HIV infection, [19]
data on its role as a prognostic marker of immune status are still
scarce. SDF-1/CXCL12 is the most primitive chemokine that regu-
lates development in multiple systems and diverse cell functions,
including proliferation and survival in the immune system,
through the two known receptors CXCR4 and ACKR3. [13,15,20]
Interestingly, the affinity of CXCL12/SDF-1 for CXCR4 correlates
well with its action as a suppressor of infection by T-tropic HIV-1species and its ability to induce CXCR4 internalization. [21] In this
context, the observed adverse effect of SDF-1 gene expression on
the natural history of HIV-1 disease could be explained by the fact
that the SDF-130T allele was more likely to be associated with
detectable X4- tropic viruses. [22] Consistent with these data, we
observed that the expression of the CXCL12 gene influenced circu-
lating SDF-1 concentrations in IRs, and according to Restrepo et al.,
[23] the expression of CXCL12 rs1801157 TT genotypes was associ-
ated with a higher probability of CD4 T-cell recovery failure in HIV
patients despite complete viral suppression with cART. In fact, we
observed that all cases included in the study carrying the CXCL12
rs1801157 TT genotypes were associated with INRs, and in con-
trast, the number of participants carrying the CXCL12 rs1801157
CC genotypes were higher in the group of IRs compared to the
group of INRs (P = 0.065). By using the HaploReg software, we
found that the CXCL12 rs1801157 is in high LD with SNPs involved
Table 3
Association between CXCL12 and CCL5 gene variants to immunological recovery status after 48 weeks of cART.
Polymorphism IHT model Genotype INR IR OR (95% CI) P-value AIC BIC
A) CXCL12 rs1801177 was associated to the immune recovery status after 48 weeks of cART. Data analysis is summarized with n (%), odds ratio (OR) and 95% confidence
interval (CI). The AIC and BIC values were used to choose the inheritance model (IHT) (adjusted by baseline CD4+ T-cell counts) that best fits the data. AIC, Akaike Information
Criteria; BIC, Bayesian Information Criteria.
rs1801157 C>T Codominant C/C 64 (66.7%) 73 (70.9%) 1.00 0.038 249.6 262.8
C/T 27 (28.1%) 30 (29.1%) 0.86 (0.441.68)
T/T 5 (5.2%) 0 (0%) 0.00 (0.00-NA)
Dominant C/C 64 (66.7%) 73 (70.9%) 1.00 0.34 253.3 263.2
C/T-T/T 32 (33.3%) 30 (29.1%) 0.73 (0.381.39)
Recessive C/CC/T 91 (94.8%) 103 (100%) 1.00 0.012 247.8 257.7
T/T 5 (5.2%) 0 (0%) 0.00 (0.00-NA)
Overdominant C/C-T/T 69 (71.9%) 73 (70.9%) 1.00 0.82 254.1 264
C/T 27 (28.1%) 30 (29.1%) 0.93 (0.481.80)
Polymorphism Cases-Controls INR-IR
D’ r P-value D’ r P-value
B) Linkage disequilibrium analysis for CCL5 gene variants.
rs2280789- rs2280788 0.9965 0.4176 < 0.001 0.9964 0.3794 < 0.001
rs2280789- rs2107538 0.9995 0.7398 < 0.001 0.9995 0.7723 < 0.001
rs2280789-rs2107538 0.9961 0.3090 < 0.001 0.9961 0.2931 < 0.001
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changes. In the light of these results, protective role of the CXCL12
rs1801157 C-allele and CC genotype in chronic lymphocytic leu-
kaemia development was observed, whereas the presence of the T
variant was linked with the higher risk of the disease as well as
impaired response to the therapy independently of the regimen
used. Interestingly, the presence of the CXCL12 rs1801157 variant
may be related with a decrease of CXCL12 and increase of its recep-
tor (CXCR4) mRNA expression levels. [24]
The other chemokine that played a potential role in immune
reconstitution was MCP-1/CCL2; increased baseline values were aTable 4
General characteristics for the genetic study of CX3CR1, CCR2 and CCR5 gene variants
Polymorphism Chr Position Genotype Cases Co
CX3CR1rs3732378_814 G>A chr3:39,265,671 GG 153 (73%) 17
GA 54 (26%) 4
AA 2 (1%)
CX3CR1 rs3732379 C>T chr3:39,265,765 CC 111 (54%) 11
CT 83 (4%) 8
TT 11 (5%) 1
CCR2 rs1799864 G>A chr3:46,357,717 GG 175 (82%) 18
GA 37 (17%) 3
AA 2 (1%)
CCR5 rs2734648 G>T chr3:46,370,349 GG 78 (38%) 7
GT 96 (47%) 10
TT 31 (15%) 4
CCR5 rs1799987 A>G chr3:46,370,444 AA 59 (28%) 5
AG 107 (51%) 10
GG 44 (21%) 5
CCR5 rs1799988 C>T chr3:46,370,768 CC 59 (30%) 6
CT 98 (49%) 10
TT 41 (21%) 5
CCR5 rs1800023 A>G chr3:46,370,817 AA 82 (40%) 8
AG 92 (45%) 10
GG 31 (15%) 3
CCR5 rs1800024 C>T chr3:46,371,068 CC 169 (79%) 18











108 (87%) 20good marker of poor immune prognosis, accounting for approxi-
mately 3% of the variance in CD4+ T cells after 48 weeks of treatment.
MCP-1/CCL2 is an inflammatory chemokine produced by several
types of cells and a chemoattractant for CD4+ T cells, monocytes/mac-
rophages, and NK cells, recruiting them to the sites of infection and
inflammation. [13,15] High CCL2/CCR2 levels were previously linked
to several HIV-associated disorders through leukocyte recruitment
and maintenance of the inflammatory status, [13,15,16,25] but their
association with previous poor immune reconstitution in HIV partici-
pants on ART has been poorly studied, and the results remain unclear.
In the present study, we found an association between the CCR2.
ntrol P-value Cases P-value HWE
INR IR Control INR IR
1 (76%) 0.379 68 (72%) 78 (76%) 0.517 0.55 0.68 1
9 (22%) 26 (27%) 23 (23%)
5 (2%) 1 (1%) 1 (1%)
8 (55%) 0.733 47 (51%) 58 (58%) 0.347 0.49 0.28 0.59
0 (37%) 41 (45%) 35 (35%)
7 (8%) 4 (4%) 7 (7%)
4 (83%) 0.980 74 (76%) 88 (85%) 0.076 1 0.35 0.16
7 (17%) 23 (24%) 14 (13%)
2 (1%)  2 (2%)
6 (34%) 0.583 34 (37%) 40 (40%) 0.919 0.58 1 1
4 (47%) 44 (47%) 46 (46%)
2 (19%) 15 (16%) 14 (14%)
8 (26%) 0.565 26 (27%) 28 (27%) 0.946 0.79 0.54 1
9 (49%) 52 (54%) 52 (51%)
6 (25%) 19 (20%) 22 (22%)
2 (28%) 0.842 28 (30%) 28 (30%) 0.851 0.34 1 1
2 (47%) 47 (51%) 46 (49%)
5 (25%) 18 (19%) 20 (21%)
5 (38%) 0.515 36 (38%) 42 (42%) 0.856 0.40 0.83 0.87
7 (45%) 43 (46%) 44 (44%)
8 (17%) 15 (16%) 14 (14%)
1 (82%) 0.749 70 (74%) 86 (82%) 0.047 1 0.36 0.08
8 (17%) 25 (26%) 16 (15%)
2 (1%)  3 (3%)
2 (10%) 0.226 15 (16%) 8 (8%) 0.049   




























































































































































































































































































































































































































































































































10 E. Yeregui et al. / EBioMedicine 62 (2020) 103077rs1799864_814 AG genotype and the probability of presenting poor
immune reconstitution after cART, which corroborates the recent
work presented by Restrepo et al. [23] By using HaploReg software,
we found that CCR2 rs1799864 is in very high LD with numerous
SNPs implicated in the promotion and enhancement of histone
marks, protein binding and motif changes. In fact, the stability or
expression of CCR2 was previously related to Alzheimer’s disease
(AD) and mild cognitive impairment (MCI) as a consequence of
higher MCP-1 levels associated with the A allele of CCR2 rs1799864.
[26]
The CCR5 chemokine receptor receives great attention in the con-
text of viral infection due to its role as an HIV-1 coreceptor [27] and
because it is a natural ligand of multiple chemokines, including MIP-
1a/CCL-3, MIP-1b/CCL-4, and RANTES/CCL-5. [2729] In fact, chemo-
kine receptors are firmly considered important therapeutic targets
for the treatment of many human diseases, [30] and the dual CCR5/
CCR2 targeting is emerging as a therapeutic strategy for complex
human diseases, including HIV infection. [29] We found that the D32
homozygous genotype was related to poor immune recovery status
and that the CCR5 rs1800024 CT polymorphism was significantly
associated with INRs. CCR5D32 exerts a robust phenotypic effect on
CCR5, [28] and CCR5D32 mutations were previously associated with
differential gene expression which in most cases is critical for the
immune response. [31] Moreover, the most interesting agreement
with the literature is the synergy between CCR2 rs1799864_814 and
CCR5 rs1800024, both located on chromosome 3. Mutations in CCR2
rs1799864 and CCR5 rs1800024 were found to predict HIV transmis-
sion, [32] but nothing has been described in relation to immune
recovery status until now. The multiple SNP analysis showed a high
LD between CCR2 rs1799864_814 and CCR5 rs1800024, and the
expression of the CCR2 rs1799864_814 AG genotype was signifi-
cantly related to increased plasma RANTES concentrations in INR par-
ticipants. In this context, our data also revealed that the alleles of
different genes in the same chromosome are inherited together more
often than would be expected by chance. Notably, two haplotypes
(GCGTGTGCA and ATGGACACA) resulting from combined CX3CR1,
CCR2 and CCR5 chemokine receptor gene expression were associated
with the immune response based on the CD4+ T-cell counts after 48
weeks of cART. Taken all together, our data supports the proof-of-
concept studies of experimental chemokine receptors as promising
candidates for advanced clinical trials. From the three chemokine
antagonist that have been approved yet, one of them is a non-com-
petitive allosteric that targets the chemokine recognition site 2 of
CCR5 to stabilize the chemokine receptor in an inactive conformation.
[30] It is Maraviroc, a small well-tolerated molecule approved by the
US FDA to treat HIV-1 infection with special interest in participants
with CCR5 tropism because their capability to prevent the binding of
chemokine and HIV gp120. Additionally, other phase 3 trials are
ongoing to evaluate this capability of CCR5 to be a potential thera-
peutic candidate (e.g. leronlimab or cenicriviroc), but of interest is
cenicriviroc. Cenicriviroc is a well-tolerated dual CCR2 and CCR5
antagonist that has been evaluated for the treatment of liver fibrosis
in HIV-negative adults with alcoholic steatohepatitis (AURORA
study). In fact, promising data suggest that cenicriviroc could
improve hepatic inflammation, insulin resistance and liver fibrosis by
the inhibition of CCR2 monocyte recruitment which directly affects
CCL2 signaling.
A limitation of our study is that the number of patients per group
in genetic studies is not consistent with the number of samples avail-
able for the study of circulating chemokine-chemokine receptor con-
centrations, which would make our results more consistent in the
search for predictive and diseases progression markers. Recently,
Norris et al. [33] also evaluated serum levels of 30 different cytokines
(including 17 chemokines) at baseline and at one and two years after
viral control to determine whether cytokine levels correlated with
INR status, and minimal differences were observed between IRs and
Fig. 5. Influence of chemokine receptor genes in circulating chemokine concentrations in INRs compared to IRs. Data are represented as the mean§SD (One-Way ANOVA testing for
association between listed parameters and SNP genotypes).
Fig. 6. Chemokine-chemokine receptor interaction analysis based on previously available data [9,10] using the STRING database [38]. The cytokine IL-7 and chemokines CCL2 to
CCL5 have been selected as input, expanded by an additional 5 proteins in the STRING interface and the confidence cut-off for showing interactions links has been set to high confi-
dence (0.700).
E. Yeregui et al. / EBioMedicine 62 (2020) 103077 11INRs. The study was performed in a group of 50 INRs compared to 50
IRs from the Women’s Interagency HIV Study and only circulating
levels were tested. Thus, the present work is the largest study evalu-
ating circulating chemokine levels and their association to genetic
chemokine and chemokine receptor variants ever done. Another
characteristic of the present study was that lower pre-cART CD4+ T
cell counts median values in INR subjects can be observed compared
to IR subjects, probably due to the relevance of the CD4+ T-cell count
before cART onset as an intrinsic risk factor of immune failure to
cART as previously described. [9,10] On the other hand, we did notinclude CCL3L1CCL4L1 copy number variation (CVN) due to their
complexity and controversial association to HIV infection. Ahuja et al.
[34] postulated that variations in the CCL3L1-CCR5 axis influences
the recovery of CD4+ T-cell counts and that the greatest impact of
these genotypes appears to be on sustaining the initial CD4+T-cell
gains after two years of cART in individuals initiating cART at more
than 350 CD4+ T-cell counts. Thus, because our study design classified
participants by their initial CD4+T-cell count, we considered that in
this study CCL3L1CCL4L1 CVN results would be biased by the study
design.
12 E. Yeregui et al. / EBioMedicine 62 (2020) 103077In conclusion, taken together, our data corroborated that the che-
mokine-chemokine receptor system is more complex than indicated
by the study of a selected chemokine and its natural ligands due to
the network existing among the different chemokines and their
receptors. We want to highlight that some therapeutic strategies
involving the use of chemokine inhibitors (e.g. Il-2, IL-7) has already
been tested but unfortunately the results obtained are still so far
away to be effective. Thus, it is very likely that new individual or
combinatorial approaches including cytokines and/or chemokines
with immune checkpoint blockage are needed to achieve complete
immune recovery status in poor immune recovery HIV-positive
patients. In the present study, we suggest that the SDF-1/CXCL12,
MCP-1/CCL-2 and CCR5 receptors are key effectors of susceptibility to
HIV progression, especially in terms of immune reconstitution. Circu-
lating concentrations and gene expression patterns of SDF-1/CXCL12
(CXCL12 rs1801157) and MCP-1/CCL2 (CCR2 rs1799864_814) are
associated with immune recovery status and could be considered
prognostic markers of immune failure despite cART. In fact, circulat-
ing concentrations of SDF-1 at 48 weeks of cART follow-up could be
considered a marker of disease progression, whereas an increase in
MCP-1 values could denote a decline in the CD4+ T-cell count. Thus, it
is not surprising that targeting CXCL12/CXCR4 axis in tumor immu-
notherapy has emerged because of its critical role in the regulation of
cancer stem cells, and in the activation of multiple signaling path-
ways (ERK1/2, ras, p38 MAPK, PLC/ MAPK, and SAPK/ JNK) for tumor
initiation and progression. [35] Pharmacological inhibition of MCP-1/
CCL2 with Spiegelmer mNOX-E36, a mirror-image oligonucleotide
with good tolerability, has been investigated as adjunct immunosup-
pressive therapy in transplantation by their ability to bind to a rele-
vant target molecule in a manner conceptually similar to the way
antibodies recognize antigens. [36] Of interest, dual blockade of
CCL2/MCP-1 and CXCL12/SDF-1 revealed additive therapeutic effects
in murine proliferative lupus nephritis because the anti-inflamma-
tory effects caused by CCL2/MCP-1 blockage and the glomerular fil-
tration barrier protection due to CXCL12/SDF-1 inhibition. [37]
Regarding CCR5 gene variants, only CCR5 rs1800024 and CCR5
rs333_814 (D32) were related to immune recovery, but interestingly,
strong LD between CCR2 rs1799864_814 and CCR5 rs1800024 indi-
cates that these alleles of each gene are inherited together more often
than would be expected by chance. In summary, our results open a
new window to proof-of-concept studies for chemokines (SDF-1/
CXCL12 and MCP-1/CCL-2) and chemokine receptors (CCR2 and
CCR5) blockage as potential therapeutic options for advanced clinical
trials with promising fortunate outcomes.
Further investigation to clarify the synergy between the expres-
sion of different chemokines and chemokine receptors could provide
new insights regarding the mechanisms implicated in the immune
reconstitution, which could be exploited for emerging therapeutic
strategies in INRs.
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